Because deregulated activation of AKT/mTOR occurs in 70% of cases of NSCLC, over-activated AKT/mTOR is a relevant therapeutic target in lung cancer as this pathway serves as the convergence for many growth stimuli, including cellular transformation, promotion of tumor invasion and angiogenesis, and resistance to chemotherapy and radiation therapy. This evidence concerns the gene AKT1 and neoplasm.